Church & Dwight rated Buy on strong organic growth and margin expansion potential

Church & Dwight is rated Buy due to strong volume-driven organic growth, market share gains, and consistent outperformance of guidance. The company’s strategy to acquire and grow underpenetrated, high-margin brands like TheraBreath and Hero supports a multi-year growth outlook. Analysts expect gross margin expansion and operating leverage to improve as comparable sales ease, with margin gains likely in the second half of this year and into 2027. Currently trading below its historical valuation, Church & Dwight offers potential for multiple re-rating, estimate upgrades, and double-digit total returns.